功能年龄而非时间年龄:衰弱指数预测晚期卵巢癌结局
本研究纳入2003年1月1日至2011年12月31日期间接受初次肿瘤细胞减灭术的535例IIIC/IV期上皮性卵巢癌患者,用30项衰弱缺陷指数评估衰弱(FI≥0.15)。衰弱患者发生Accordion 3级及以上并发症和术后90天内死亡的风险更高,总生存更短;衰弱与死亡独立相关。
要点
- 衰弱(FI≥0.15)在晚期上皮性卵巢癌患者中占24.5%。
- 衰弱患者Accordion 3级及以上并发症风险更高(校正OR 1.62)。
- 衰弱患者术后90天内死亡风险更高(校正OR 2.60)。
核心结论
- 衰弱是上皮性卵巢癌患者的常见表现,与更差的手术结局和更差的总生存独立相关。
- 常规衰弱评估可纳入上皮性卵巢癌患者的咨询和决策,而不应仅依赖年龄等单一因素。
研究设计与样本
- 回顾性研究,纳入2003年1月1日至2011年12月31日期间接受初次肿瘤细胞减灭术的IIIC/IV期上皮性卵巢癌患者535例。
- 衰弱缺陷指数包含30个项目,每项评分0、0.5或1分,总分为各项之和除以项目总数,FI≥0.15定义为衰弱。
- 采用逻辑回归和Cox比例风险回归评估关联。
主要发现
- 535例患者中78%为IIIC期,平均(标准差)年龄64.3(11.3)岁,FI中位数0.08,131例(24.5%)为衰弱(FI≥0.15)。
- 衰弱患者较非衰弱患者更易发生Accordion 3级及以上并发症(28.2% vs 18.8%;OR 1.70,95%CI 1.08-2.68)。
- 衰弱患者较非衰弱患者更易在术后90天内死亡(16.0% vs 5.2%;OR 3.48,95%CI 1.83-6.61)。
- 校正已知危险因素后,上述关联仍显著:并发症aOR 1.62(95%CI 1.00-2.62);90天内死亡aOR 2.60(95%CI 1.32-5.10);另一aOR 0.57(95%CI 0.34-0.97)。
- 整个队列总生存39.6个月;衰弱患者总生存较非衰弱患者更短(中位26.5 vs 44.9个月,p<0.001)。
临床怎么用
- 作者认为,常规衰弱评估可纳入上皮性卵巢癌患者的咨询和决策,而不应仅依赖年龄等单一因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the impact of frailty as measured by a frailty deficit index (FI) on outcomes in advanced epithelial ovarian cancer (EOC) after primary debulking surgery (PDS). METHODS: Women with Stage IIIC/IV EOC who underwent PDS between 1/1/2003-12/31/2011 were included. Medical records were reviewed for patient characteristics and outcomes. The FI includes 30 items scored at 0, 0.5 or 1 and is calculated by summing across all the item scores and dividing by the total. Frailty was defined as a FI ≥0.15. Associations were assessed using logistic regression and Cox proportional hazards regression. RESULTS: Of the 535 studied, 78% had stage IIIC disease and mean (SD) age was 64.3 (11.3) years. Median FI was 0.08, and 131 patients (24.5%) were considered frail with FI ≥0.15. Compared to non-frail patients, frail patients were more likely to have an Accordion grade 3+ complication (28.2 vs. 18.8%; odds ratio (OR): 1.70, 95% CI: 1.08-2.68) and more likely to die within 90days of surgery (16.0 vs. 5.2%; OR: 3.48, 95% CI: 1.83-6.61). After adjusting for known risk factors, these associations remained significant, adjusted OR (aOR): 1.62, 95% CI: 1.00-2.62; aOR: 2.60, 95% CI 1.32-5.10; and aOR: 0.57, 95% CI 0.34-0.97, respectively. Overall survival (OS) for the entire cohort was 39.6months (m). OS was shorter in the frail versus non-frail (median 26.5 vs 44.9m, p<0.001). Frailty was independently associated with death (adjusted hazard ratio: 1.52, 95% CI: 1.21-1.92) after adjusting for known risk factors. CONCLUSIONS: Frailty is a common finding in patients with EOC and is independently associated with worse surgical outcomes and poorer OS. Routine assessments of frailty can be incorporated into patient counseling and decision-making for the EOC patient beyond simple reliance on single factors such as age.
引用
- Kumar A, Langstraat CL, DeJong SR, et al. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 28734497. doi:10.1016/j.ygyno.2017.07.126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。